Companies › Energenesis Biomedical
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ENERGI-F703 GEL Not specified | – | Phase 3 | Diabetic Foot Ulcer | – |
| ENERGI-F703EB Cream | – | Phase 2 | Epidermolysis Bullosa (EB) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05930210 | ENERGI-F703 GEL | Phase 3 | Diabetic Foot Ulcer | Metabolic and endocrine | Dec 2025 |
| NCT07858422 | ENERGI-F703EB Cream | Phase 2 | Epidermolysis Bullosa (EB) | Other | Mar 2027 |
No annotated target.
–
Biotechnology Institute IMASD BrightGene Bio-Medical Technology Soleno Therapeutics Beijing QL Biopharmaceutical CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.